Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study

Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study

“…We previously reported marked differences in the prevalence of 19 menopausal symptoms in these ethnic groups, as recorded daily on diary cards. We also observed significant beneficial effects following daily therapy with three doses of continuous combined conjugated estrogens/medroxyprogesterone acetate 9,10 .…”

“…Detailed entry requirements have been previously published 9 . In brief, healthy postmenopausal women between the ages of 40 and 65 years with an intact uterus were eligible if they had been postmenopausal for at least 12 months, as evidenced by the absence of menstrual bleeding, and if they had experienced any of a series of 18 menopausal symptoms, as evaluated by daily diary recordings during a 14-day baseline period prior to therapy.…”

“…The screening and assessment procedures have been reported in detail elsewhere 9 . Prestudy screening included a mammogram (unless performed within 12 months), gynecologic examination (including breast), cervical cytological (Pap) smear (unless performed within 3 months) and endometrial biopsy (unless performed within 3 months) or vaginal or rectal ultrasonography, as well as laboratory safety (hematology, blood chemistry, urinalysis, HIV, hepatitis B and C) evaluations.…”

Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: The Pan-Asia Menopause (PAM) study

“…Eligibility criteria for the study population have been detailed previously 23 . In brief, healthy postmenopausal women between the ages of 40 and 65 years with an intact uterus were eligible for the study if they had been amenorrheic for at least 12 months prior to screening and if they had experienced any of a set of 18 menopausal symptoms.…”

“…lipid/lipoprotein profiles in nine large ethnic groups of postmenopausal Asian women in parallel as a part of the Pan-Asia Menopause (PAM) study [23][24][25] and investigated lipid/lipoprotein changes following estrogen/progestin therapy.…”